Watson Expands Its Geographic Reach With Actavis Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
With its $5.6 billion acquisition of Actavis, Watson will be the third largest generics company in a sector of the industry where global scale and market share is becoming paramount for success.